This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Carol M. Proudfit, PhD

JAMA. 1976;236(8):939-940.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RECENT reports suggest that the administration of estrogens to postmenopausal women is associated with an increased risk of acquiring endometrial cancer. The problem was identified in retrospective studies in which postmenopausal patients with endometrial cancer were compared to matched controls with respect to their history of estrogen therapy. Ziel and Finkle¹ compared 94 endometrial cancer patients with 188 controls from the same health plan who were matched on the basis of age, area of residence, and length of time in the health plan. The estimated risk of acquiring endometrial cancer was 7.6 times higher for women who were treated with estrogens, and the risk increased with the length of time on the medication. The estimated risk increased from 5.6 times for 1 to 4.9 years of use to 13.9 times for seven or more years of use.

Smith et al² compared women with endometrial cancer to women with . . . [Full Text PDF of this Article]

Author Affiliations
From the AMA Department of Drugs, Chicago. Reprint requests to AMA Department of Drugs, 535 N Dearborn St, Chicago, IL 60610 (Dr Proudfit).

Footnotes
A technical bulletin (Estrogen Replacement Therapy) related to the subject of this article is available from the American College of Obstetricians and Gynecologists, Suite 2700, 1 E Wacker Dr, Chicago, IL 60601.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?